NYSE$HAE
Haemonetics Corp. · Q4 2024 earnings
Q4 2024 earnings · · Investor relations
Briefing
Haemonetics' Q4 2024 financial performance was strong, driven by revenue growth and margin expansion.
Haemonetics reported strong fourth quarter and fiscal year 2024 results, with revenue increasing by 13% to $343 million. The company advanced its market leadership through strategic investments and acquisitions, contributing to revenue growth and margin expansion.
- Revenue increased by 13% to $343 million in the fourth quarter of fiscal 2024.
- Organic revenue growth was 10% for the fourth quarter of fiscal 2024.
- Adjusted earnings per diluted share increased by 16.9% to $0.90 in the fourth quarter of fiscal 2024.
- The company is on track to deliver increased value to customers and shareholders.
Headline financials
Revenue & EPS history
Haemonetics · Revenue · Quarterly
$343M
Revenue by segment
Haemonetics · $313M total across 3 segments · Q2 2024
- Plasma$142M+11.0%45.3%
- Hospital$103M+13.5%32.9%
- Blood Center$68.1M-7.6%21.7%
Forward guidance
The Company issued its fiscal 2025 GAAP total revenue and organic revenue growth guidance in its updated revenue reporting format.
Tailwinds
- Total Company Reported Revenue Growth: 5-8%
- Hospital Revenue Growth: 27-32%
- Adjusted Operating Margin: 23-24%
- Adjusted earnings per diluted share: $4.45 - $4.75
- Free cash flow: $130M - $180M
Headwinds
- Plasma Revenue Growth: (3-6)%
- Blood Center Revenue Growth: (5-8)%
- Currency Impact on Total Company Revenue: (0-1)%
- Organic revenue growth: 0-3%
- Currency impact on Blood Center Revenue: (0-1)%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.4%
Avg return
Earnings day
+4.1%
Avg return
5 days after
+6.5%
Avg return
30 days after
56%
38 / 68 earnings
Positive
+31.8%
Q2 2026
Best reaction
-15.0%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +3.3% | +2.5% | +35.5% | |
| Q3 2026 | -1.4% | -9.8% | -2.8% | |
| Q2 2026 | +31.8% | +41.4% | +65.5% | |
| Q4 2025 | +5.9% | +7.6% | +9.7% | |
| Q3 2025 | -11.6% | -13.6% | -3.6% | |
| Q2 2025 | +11.8% | +19.5% | +3.9% | |
| Q1 2025 | -10.1% | -13.4% | -14.6% | |
| Q4 2024 | +2.8% | +4.4% | -8.2% | |
| Q3 2024 | -3.8% | -7.0% | +3.2% | |
| Q2 2024 | +2.4% | +2.5% | -2.5% | |
| Q1 2024 | +2.0% | +3.0% | -0.8% | |
| Q4 2023 | +7.6% | +7.4% | +6.1% | |
| Q3 2023 | -5.4% | -8.2% | -12.2% | |
| Q2 2023 | +4.1% | -1.7% | +3.5% | |
| Q1 2023 | +8.1% | +12.3% | +13.7% | |
| Q4 2022 | +3.9% | +14.1% | +31.5% | |
| Q3 2022 | +21.2% | +24.5% | +18.9% | |
| Q2 2022 | -13.5% | -15.7% | -24.8% | |
| Q1 2022 | +8.4% | +1.8% | +16.8% | |
| Q4 2021 | -6.4% | -5.4% | +0.4% | |
| Q3 2021 | +12.8% | +21.1% | +4.0% | |
| Q2 2021 | -3.7% | +5.6% | +13.2% | |
| Q1 2021 | -12.7% | -8.5% | +3.3% | |
| Q4 2020 | -8.8% | -3.4% | -11.1% | |
| Q3 2020 | +7.2% | +7.7% | -7.3% | |
| Q2 2020 | +0.3% | +0.5% | -0.1% | |
| Q1 2020 | +10.5% | +13.5% | +10.8% | |
| Q4 2019 | +2.8% | +3.4% | +10.0% | |
| Q3 2019 | -12.2% | -14.3% | -13.0% | |
| Q2 2019 | +9.1% | +5.8% | -0.2% | |
| Q1 2019 | +4.8% | +2.7% | +14.4% | |
| Q4 2018 | +5.8% | +11.2% | +18.9% | |
| Q3 2018 | +14.8% | +13.1% | +20.5% | |
| Q2 2018 | +15.8% | +16.4% | +20.8% | |
| Q1 2018 | +4.2% | +3.2% | +3.9% | |
| Q4 2017 | -1.9% | -4.4% | -4.0% | |
| Q3 2017 | -10.1% | -9.0% | -7.3% | |
| Q2 2017 | +10.5% | +13.8% | +16.5% | |
| Q1 2017 | +13.8% | +16.8% | +22.6% | |
| Q4 2016 | -15.0% | — | — | |
| Q3 2016 | +5.9% | — | — | |
| Q2 2016 | -3.9% | — | — | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +7.0% | — | — | |
| Q2 2015 | -5.9% | — | — | |
| Q1 2015 | -1.4% | — | — | |
| Q4 2014 | -8.0% | — | — | |
| Q3 2014 | -2.6% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | -1.4% | — | — | |
| Q3 2013 | -5.6% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -0.1% | — | — | |
| Q4 2012 | +4.2% | — | — | |
| Q3 2012 | -1.0% | — | — | |
| Q2 2012 | +0.4% | — | — | |
| Q1 2012 | +3.1% | — | — | |
| Q4 2011 | +1.3% | — | — | |
| Q4 2009 | +1.3% | — | — | |
| Q3 2010 | -1.3% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | +1.7% | — | — | |
| Q1 2010 | -2.5% | — | — | |
| Q2 2010 | -2.5% | — | — | |
| Q1 2011 | -2.5% | — | — | |
| Q4 2010 | -2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro